Skip to main content

Table 1 Study population

From: Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis

Parameters Me (IQR), n = 37
Females, n (%) 21/37 (56.8)
Age of the start TCZ, years 10.2 (6.0-12.8)
TCZ delay, months 36.0 (10.7-97.0)
SoJIA related symptoms at the start of TCZ, n (%)  
- fever 28 (75.7)
- rash 24 (73.0)
- hepatomegaly 20 (54.1)
- lymphadenopathy 13 (35.1)
- splenomegaly 11 (29.7)
- heart involvement 10 (27.0)
- interstitial lung disease 6 (16.2)
- CNS dysfunction 6 (16.2)
- coagulopathy with hemorrhage 4 (10.8)
Hemoglobin, g/dl 11.0 (10.3 – 12.1)
WBC, *109/l 11.9 (7.9 – 16.1)
Granulocytes, cells in 1 μl 7812.0 (5530.0 – 13202.0)
CRP, mg/l 35.0 (11.6 – 88.5)
ESR, mm/h 42.0 (22.0 – 54.0)
Platelets *109/l 361.0 (299.0 – 465.0)
Ferritin, mg/ml 197.0 (84.0 – 841.0)
LDH, U/l 513.0 (425.0 – 743.0)
Albumin, g/dl 3.0 (2.5 – 3.2)
Number of active joints at the start of TCZ 7.0 (2.0 – 22.0)
no active joints, n (%) 4 (10.8)
< 5 active joints, n (%) 13 (35.1)
≥5 active joints, n (%) 20 (54.1)
Treatment before TCZ administration:  
- Corticosteroids, n (%) 26 (70.3)
- mean dose, mg/kg 0,73
- Methotrexate, n (%) 32 (86.5)
- mean dose, mg/m2/week 14,7
- Cyclosporine A, n (%) 20 (54.1)
- mean dose, mg/kg 4,2
Combination 18 (48.7)
MAS before TCZ administration, n (%) 12 (32.4)
  1. *Pts # 27, 32 have developed infusion reaction and MAS coincidently; pt # 20 had only infusion reaction leads to TCZ discontinuation, Me – median, IQR –interquartile ranges.